HTL’s Executive Committee is composed of highly experienced professionals with international backgrounds.
Chief Executive Officer
François Fournier joined HTL Biotechnology in September 2022 as Chief Executive Officer (CEO).
François Fournier is a seasoned Franco-American healthcare executive who brings to this role over 25 years of experience in leadership, commercial regional functions, corporate roles, as well as an expertise of HTL’s therapeutic areas, especially dermatology and medical esthetics. Prior joining HTL, he was CEO from end of 2018 to August 2022 of Virbac North America, one of the leading animal health pharmaceutical companies. He previously held several international positions at pharmaceutical companies, at Smith & Nephew and Galderma (joint venture between L'Oréal and Nestlé) as President of North America. He is also a board member of Solascure a pharmaceutical company with a wound care product in development.
He holds a Ph.D. in Pharmacy from the University of Reims Champagne-Ardenne (France) and Berlin (Germany) as well as a master’s degree in business Intelligence from the business school HEC Paris. He is fluent in French, English, and German.
Global Chief Operating Officer
Yvon Bastard is the Global Chief Operating Officer (COO) of HTL since September 2022.
Yvon Bastard is a scientist who brought to the company more than 30 years of experience in the pharmaceutical sector, a strong leadership, as well as an expertise of R&D and manufacturing processes in the biopolymer sector. Prior being appointed Global COO, he was Chief Operating Officer of HTL from 2017 to 2022. Before joining the company, he had multiple leadership roles in several pharmaceutical companies including at Axyntis Group, a French CDMO in fine organic chemistry, involved in pharmaceutical and electronic APIs, Kyrapharm which specializes in the industrial purification of high-value molecules by HPLC, and from 1989 strongly contributed to the foundation and growth of the Pharmaceutical Division of 3M, the US based company.
He holds a master’s degree in Organic Chemistry from Rennes (France) and a degree in Molecular Chemistry from Rennes University (France).
Chief Scientific Officer
Anthony Bresin is the Chief Scientific Officer of HTL since March 2018.
Anthony Bresin brings more than 20 years of experience in the industrial biotechnology domain, mainly in fermentation and purification with a specific focus on the scale-up from laboratory to industrial scale. Prior joining HTL, he held several leadership and R&D positions in biotechnology companies specialized in the production of biopolymers including at ARD, a French-based contract research organization (CRO) company owned by Vivescia Industry and at BioAmber, a company dedicated to the production of succinic acid by fermentation.
He holds a Ph.D in Industrial Fermentation on hyaluronic acid production from Reims Champagne Ardennes University (France).
Chief Commercial Officer
Laurène Brodiez is the Chief Commercial Officer of HTL since July 2021.
Laurène Brodiez has a solid experience in analytics, marketing, and sales force management, in leading strategic projects at an executive level, as well as growing sales in an international environment. Prior joining HTL, she had different roles at Sanofi including as General Manager North America for Sanofi Active Ingredients Solutions based in New Jersey (USA), chief of staff of the General Manager France, and Head of Sales representatives.
She holds a master’s degree in Advances Biotechnologies from ESIEE Management in Paris (France) and a bachelor degree in Cellular Biology.
Chief Industrial Performance Officer
Christophe Coyard is the Chief Industrial Performance Officer of HTL since April 2020.
Christophe Coyard brings to this role over 25 years of industrial experience gained in both the automotive and pharmaceutical sectors. Prior joining HTL, he held leadership roles in various GSK manufacturing sites where he acquired experience in industrial project management in a highly regulated environment. He also developed his expertise in lean manufacturing management and engineering working for automotive suppliers.
Christophe Coyard holds an Engineering degree from the Ecole des Arts et Métiers (France).
Chief Quality & Compliance Officer
Marie-Armelle Floc’h is the Chief Quality and Compliance Officer of HTL since June 2019.
Marie-Armelle Floc’h has more than 25 years' experience in Quality Control, Quality Assurance and project management in the pharmaceutical industry. Prior joining HTL, she held the position of Senior Quality Manager at GSK, a worldwide vaccines production site. From 2001 to 2013, she held various executive positions at Ceva (pharmaceutical industry), such as Quality Control Manager or Project Manager Officer.
She holds a master's degree in Quality Assurance from Nantes University (France) and a degree in Chemical Engineering.
Chief Strategy and Transformation Officer
Bertrand Hurtault is the Chief Strategy and Transformation Officer of HTL since August 2019.
Bertrand Hurtault has served more than te years as a consultant at KPMG Strategy Group where he actively participated in creating and developing the Healthcare and Life Sciences Strategy practice. As a principal, he mostly supported private equity firms in their investment strategy as well as over post-deal value creation programmes on both strategic and operational sides. He also led large lobbying projects for public institutions or union associations and supported several large companies in their IPO process. Prior joining HTL, Mr. Hurtault started his career as a strategic and financial analyst at Varenne Capital Partners, a value investing oriented mutual fund.
He is graduated from Paris-Assas University where he obtained a degree in Corporate and Market Finance, with a specialization in data analytics.
Chief HR Officer
Emmanuel Lefèvre joined HTL Biotechnology October 2022, as Chief HR Officer (CHRO).
Emmanuel Lefèvre brings 25 years of HR operational and strategic leadership experiences, successfully built in France and internationally, within fast growing and high technology industries such as life sciences, coding-marking, food ingredient and health.
Prior joining HTL Biotechnology, he was the HR VP of the Taste, Nutrition and Health segment of Symrise, that he joined in 2018. Previously, Emmanuel held several international HR management roles within Dover for Markem-Imaje, in particular in Switzerland as Global HR VP between 2013 and 2018.
Earlier in his career, Emmanuel Lefèvre got his postgraduate degree in Human Resources from the Paris Pantheon-Sorbonne University, before taking as first career steps HR consulting and Learning & Development positions.
Chief Operating Officer
Cyril Picault was appointed Chief Operating Officer of HTL in January 2018.
Cyril Picault has more than 15 years of executive experience in manufacturing processes for API, maintenance and supply chain. Prior to this position Cyril started his career in HTL as Production Manager from 2003 to 2018.
He holds a Master of Engineering from the AgroParisTech (France) and obtained a training degree in Global Operation Managment at the University of Irvine (United States).
Chief Financial Officer
Nicolas Préfol joined HTL in September 2022 as Chief Financial Officer (CFO).
Nicolas Préfol has more than 20 years’ experience in international industrial companies, with a specific focus on Finance. Prior to joining HTL, he was the CFO and Secretary general for Segro Group, the leading independent manufacturer of Cartesian robots in Europe. Previously, he worked for General Electric driving growth and profitability in the group’s international divisions (Germany, USA, Australia, Italy, Switzerland) as well as an assignment as CFO in France.
He is a graduate of both the University of Paris Dauphine (International Business), and of Toulouse Business School (Finance and Management).
Crédit Photo : Agence Brunet-Monié